Intracavernosal forskolin: Role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1752-1758

  Mulhall, John P ^a   Daller, Meir ^a   Traish, Abdulmaged M ^a   Gupta, Sandeep ^a   Park, Kwangsung ^a   Salimpour, Pedram ^a   Payton, Terry R ^a   Krane, Robert J ^a   Goldstein, Irwin ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic AMP; Forskolin; Impotence

Indexed keywords

FORSKOLIN; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; PROSTAVASIN;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RABBIT; REGIONAL PERFUSION; SELF INJECTION;

EID: 0030796819     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64118-1     Document Type: Article

References (42)

1. Linet, O. L., Ogrinc, F. G. and The Alprostadil Study Group: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New Engl. J. Med., 334: 873, 1996.
2. Goldstein, I., Abobakr, R., Hakim, L., Kulaksigzoglu, H., Payton, T. and Albrecht, D.: Prospective comparison of the EDEX™ Office intracavernosal injection test with re-dosing dynamic pharmacocavernosography. Int. J. Impot. Res., 8: 110, 1996.
3. Porst, H.: The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol., 55: 802, 1996.
4. Fallon, B.: Intracavernous injection therapy for male erectile dysfunction. Urol. Clin. North Amer., 22: 833, 1995.
5. Virag, R., Shoukry, K., Floresco, J., Nollet, F. and Greco, E.: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J. Urol., 145: 287, 1991.
6. Hall, S., Honig, S. C., Payton, T. R., Krane, R. J. and Goldstein, I.: Use of atropine sulfate in pharmacologic erection: initial experience with one year follow-up in the United States. J. Urol., part 2, 147: 265A, abstract 206, 1992.
7. Montorsi, F., Guazzoni, G., Bergamaschi, F., Dodesini, A., Rigatti, P., Pizzini, G. and Miani, A.: Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence. Urology, 42: 554, 1993.
8. Cahn, D., Melman, A., Valcic, M. and Christ, G. J.: Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J. Urol., 155: 1789, 1996.
9. Seamon, K. B. and Daly, J. W.: Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleo-tide regulatory protein. J. Biol. Chem., 256: 9799, 1981.
10. Seamon, K. B. and Daly, J. W.: Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J. Cyclic. Nuc. Res., 7: 201, 1981.
11. Sparwasser, C., Drescher, P., Will, J. A. and Madsen, P. O.: Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms. J. Urol., 152: 2159, 1994.
12. 45Ca influx, net Ca uptake and tension in rabbit aortic smooth muscle. Eur. J. Pharmacol., 134: 155, 1987.
13. Saenz de Tejada, I., Moroukian, P., Tessier, J., Kim, J. J., Goldstein, I. and Frohrib, D.: The trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am. J. Physiol., 260: H1590, 1991.
14. Moreland, R. B., Traish, A. M., McMillin, M. A., Smith, B., Goldstein, I. and Saenz de Tejada, I.: PGE1 suppresses the induction of collagen synthesis by transforming growth factor-B1 in human corpus cavernosum smooth muscle. J. Urol., 153: 826, 1995.
15. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J.: Protein measurements with the Folin phenol reagent. J. Biol. Chem., 193: 265, 1951.
16. National Institutes of Health: Consensus development conference statement on impotence. Int. J. Impot. Res., 5: 181, 1993.
17. Krane, R. J., Goldstein, I. and Saenz de Tejada, I.: Impotence. New Engl. J. Med., 321: 1648, 1989.
18. Jünemann, K.-P. and Alken, P.: Pharmacotherapy of erectile dysfunction: a review. Int. J. Impot. Res., 1: 71, 1989.
19. Strachan, J. R. and Pryor, J. P.: Diagnostic intracorporeal papaverine and erectile dysfunction. Brit. J. Urol., 59: 264, 1987.
20. Kapoor, V. K., Chahal, A. S., Jyoti, S. P., Mundkur, Y. J., Kotwal, S. V. and Mehta, V. K.: Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia, 31: 675, 1993.
21. Chen, J. K., Hwang, T. I. and Yang, C. R.: Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Brit. J. Urol., 69: 404, 1992.
22. Buvat, J., Lemaire, A., Marcolin, G., Dehaene, J. L. and Buvat-Herbaut, M.: Intracavernous injection of papaverine: assessment of its diagnostic and therapeutic value in 100 impotent patients. World J. Urol., 5: 150, 1987.
23. Bodner, D. R., Lindan, R., Leffler, E., Kursh, E. D. and Resnick, M. I.: The application of intracavernous injection of vasoactive medications in men with spinal cord injury. J. Urol., 138: 310, 1987.
24. Robinette, M. A. and Moffatt, M. J.: Intracorporeal injection of papaverine and phentolamine in the management of impotence. Brit. J. Urol., 58: 692, 1986.
25. Sidi, A. A., Reddy, P. K. and Chen, K. K.: Patient acceptance and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J. Urol., 140: 293, 1988.
26. Stief, C. G., Benard, F., Bosch, R. J. L. H., Aboseif, S. R., Lue, T. F. and Tanagho, E. A.: A possible role for calcitonin-gene related peptide in the regulation of the smooth muscle tone of the bladder and penis. J. Urol., 143: 392, 1990.
27. Stief, C. G., Holmquist, F., Allhoff, E. P., Andersson, K.-E. and Jonas, U.: Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue in vivo. World J. Urol., 9: 237, 1991.
28. Buvat, J., Lemaire, A., Buvat-Herbaut, M. and Marcolin, G.: Safety of intracavernous injections using an alpha-blocking agent. J. Urol., 141: 1364, 1989.
29. Azadzoi, K. M., Payton, T., Krane, R. J. and Goldstein, I.: Effects of intracavernosal trazodone hydrochloride: animal and human studies. J. Urol., 144: 1277, 1990.
30. Wagner, G. and Gerstenberg, T.: Vasoactive intestinal polypeptide facilitates normal erection. In: Proceedings of the Sixth Biennial International Symposium for Corpus Cavernosum Revascularization and Third Biennial World Meeting on Impotence. Boston, Massachusetts, October 6-9, 146: 1988.
31. Kilic, S., Salih, M., Anafarta, K., Baltaci, S. and Kosar, A.: Adenosine: a new agent in the diagnosis of impotence. Int. J. Impot. Res., 6: 191, 1994.
32. Abe, A. and Karaki, H.: Inhibitory effects of forskolin on vascular smooth muscle of rabbit aorta. Jap. J. Pharmacol., 46: 293, 1988.
33. ++ levels and contraction in vascular smooth muscle. J. Pharm. Exper. Ther., 249: 895, 1989.
34. 2+ pump by cyclic nucleotides in cultured vascular smooth muscle. J. Biol. Chem., 263: 8058, 1988.
35. Bülbring, E. and den Hertog, A.: The action of isoprenaline on the smooth muscle of the guinea-pig taenia coli. J. Physiol., 304: 277, 1980.
36. Meisheri, K. D. and Van Breemen, C.: Effects of beta-adrenergic stimulation on calcium movements in rabbit aortic smooth muscle: relationship with cyclic AMP. J. Physiol., 331: 429, 1982.
37. + sequestration in beta-adrenergic relaxation of a smooth muscle. Nature, 281: 682, 1979.
38. Scheid, C. R., Honeyman, T. W. and Fay, F. S.: Mechanism of beta-adrenergic relaxation of smooth muscle. Nature, 277: 32, 1979.
39. Haynes, J., Robinson, J., Saunders, L., Taylor, A. E. and Strada, S. J.: Role of cAMP-dependent protein kinase in cAMP-mediated vasodilatation. Am. J. Physiol., 262: H511, 1992.
40. Roth, D. A., Urasawa, K., Helmer, G. A. and Hammond, K. H.: Downregulation of cardiac guanosine 5′-triphosphate-binding protein in right atrium and left ventricle in pacing-induced congestive heart failure. J. Clin. Invest., 91: 939, 1993.
41. Sanbe, A. and Takeo, S.: Effects of NKH477, a water-soluble forskolin derivative, on cardiac function in rats with chronic heart failure after myocardial infarction. J. Pharm. Exper. Ther., 274: 120, 1995.
42. Caprili, J. and Sears, M.: Forskolin lowers intraocular pressure in rabbits, monkeys and man. Lancet, 2: 958, 1983.